Type I (insulin-dependent) diabetes mellitus results from the selective destruction of pancreatic beta cells and is considered to be a cell-mediated autoimmune disease [1] . To understand the pathogenesis of the disease better we studied pancreatic biopsy specimens from recent-onset Type I diabetic patients. These studies showed hyperexpression of MHC class I antigens and that the predominant islet-infiltrating cells to be CD8 + T cells and macrophages [2±3]. Others have examined autopsy specimens from Type I diabetic patients and have reported similar immunohistological findings [4±6].
teristic immunohistological findings of insulitis or MHC class I hyperexpression or both [2±3] . The patients whose biopsies did not show either insulitis or MHC class I hyperexpression otherwise manifested all the typical Type I diabetic clinical characteristics. Similar patients have been reported among Caucasians [5, 7] . They were diagnosed using clinical criteria as having typical Type I diabetes but minimal or no insulitis was observed in their pancreas specimens at autopsy. These findings suggest that Type I diabetes is an immunohistologically heterogeneous disease with perhaps a more multi-factorial pathophysiology than is currently appreciated.
Recently, the expert committee on the diagnosis and classification of diabetes mellitus proposed that Type I diabetes resulted from mainly ªimmune-mediatedº beta-cell destruction, except for a few ªidiopath-icº cases [8] . Nevertheless, detailed immunohistological features have not been correlated with temporal changes in clinical status. We therefore studied the immunohistological features present in pancreatic biopsy specimens from patients with recent-onset Type I diabetes and followed the clinical status of these patients for 2 or more years after the onset of the disease.
Subjects and methods
Patients. Patients (n = 17) with recent-onset diabetes clinically consistent with the early Type I disease were recruited for this study. Accordingly, all patients were lean and presented with some degree of ketosis. They were therefore started immediately on insulin therapy. Only patients with an initial C-peptide excretion of 5 mg/day were included in the study because we wished to study the effect of immunohistological abnormalities on the beta-cell function still present when diabetes first became clinically manifest. Written informed consent was obtained from all the study patients before the pancreatic biopsy was carried out as previously reported [2±3]. The 17 patients were then divided into two groups based on the immunohistological analysis of their biopsy specimen. Those patients (n = 11, 1±11 on Table 1 ) who displayed insulitis or the hyperexpression of MHC class I antigens or both were designated the autoimmune-proven (AP) group. The biopsies from six patients (12±17 on Table 1 ) displayed no immunological abnormalities and this group was designated the autoimmune-unproven (AUP) group. The time from diagnosis to biopsy was similar for the two groups; 3.3 months (range 1±7 months) for the AP and 3.5 months (range 0±7 months) for the AUP group.
HLA typing and clinical characteristics at diagnosis. At the time of the diagnosis we documented: age, sex, body mass index (BMI), HbA 1C , urinary C-peptide secretion, presence or absence of a family history of diabetes and presence or absence of probable infection preceding diabetes onset. In addition, we determined HLA class I and class II subtypes.
Islet autoantibodies. At the time of the biopsy, we also assayed each patient's serum for islet cell antibodies (ICA) and GADAb using an indirect immunofluorescent method and a radioimmunoassay, respectively [9] . Values greater than 5 Juvenile Diabetes Foundation Units (JDFU) were considered positive for the ICA and greater than 5 U/ml were considered positive for the GAD-Ab. The fourth and fifth ICA proficiency tests done under the auspices of the Immunology and Diabetes Workshops determined that our laboratory had a 100 % sensitivity and specificity.
Long-term clinical features. All patients were admitted to hospital for their pancreatic biopsy and were subsequently followed in our diabetes outpatient clinic. All patients were treated with multiple daily insulin injections and self-monitored their blood glucose aiming to maintain normoglycaemia. Each patient's daily insulin doses were monitored and documented once a month. Each patient visited the laboratory once a month for a fasting plasma sugar and HbA 1C determination.
Statistical analysis. Statistical analysis was by Chi-squared test, Mann-Whitney U test or Student's t-test where appropriate. 
Results
Immunological and immunohistological analysis. All immunological and immunohistological data for the 17 patients is shown in Table 1 . In the six AUP patients, six DQB1 alleles are considered to be diabetes susceptible and two to be neutral. In the 11 AP patients, 14 DQB1 alleles are considered to be diabetes susceptible, 5 neutral and 1 resistant for Type I diabetes [10] . Although the sample is small, we observed no significant difference between the AP and AUP patients in HLA class I and class II antigens and the genotype of HLA-DRB1 or DQB1 antigens. Typical photomicrographs showing the appearance of an inflamed islet (insulitis) compared with an un-infiltrated islet together with an islet with increased MHC class I expression as opposed to one with the more typical faint expression are represented in Fig. 1 . All 17 patients were found to harbour residual beta cells. We examined, on average ( ± SD), 104 ( ± 98) islets in AP patients and 60 ( ± 45) islets in the AUP patients. In those biopsy specimens showing insulitis and using an islet counting method we have reported previously [3] , we found 20.9 ± 22.6 % of the islets to be affected islets (means ± SD). Immunological abnormalities in islets were correlated with the existence of GAD-Ab (p < 0.05, chi-squared analysis).
Clinical characteristics at diabetes onset. At the time of diabetes diagnosis, there were no significant differences between AP and AUP patients in (all data expressed as mean ± SD): age (29.7 ± 8.7, 24.0 ± 8.5), sex (men/women = 7/4, 4/2), BMI (18.8 ± 1.9, 17.2 ± 2.0), HbA 1C values (11.0 ± 2.4, 11.4 ± 1.4) and urinary C-peptide secretion (22.7 mg/day ± 11.6, 32.3 mg/day ± 7.9). None of the patients had a relative with Type I diabetes but 6 of the 11 patients in the AP group and 5 of the 6 patients in AUP group had relatives with Type II (non-insulin-dependent) diabetes mellitus. Signs or symptoms suggesting antecedent infection were observed in 4 of the 11 AP patients and 4 of the 6 AUP patients. Lastly, at diagnosis there was no significant difference between AP and AUP patients in fasting plasma glucose, HbA 1C or daily insulin dose (Fig. 2) .
Clinical characteristics on follow-up. Although fasting plasma glucose concentrations in AUP patients did not change over the 2-year observation period after pancreatic biopsy, these concentrations increased in the AP patients (p < 0.05) (Fig. 2) . The HbA 1C values were also higher in the AP than in the AUP group at the end of this period (p < 0.05, Fig. 2 ), another indication of a gradual deterioration in control in the AP patients. Finally, we observed better glycaemic control in the AUP group despite their daily insulin requirements being lower than those of AP patients.
Discussion
We report that immunohistological analysis of pancreatic biopsy specimens correlates with the heterogeneous clinical course of Type I diabetes after initial diagnosis. Insulitis or MHC class I hyperexpression or both was observed in 11 of the 17 patients and their glycaemic control deteriorated during the post-diagnosis 2-year follow-up period. On the other hand, 6 of 17 patients did not show the immunohistological changes at diagnosis and their glycaemic control was better despite relatively smaller daily insulin doses during the 2-year post-diagnosis follow-up. The improved glycaemic control with small insulin doses observed in the AUP group almost certainly reflects residual beta-cell function [11±12]. After the onset of Type I diabetes, the patients in which islet immunological abnormalities had been observed probably gradually lost their remaining beta-cells (insulin-secreting capacity) resulting in the deteriorating glycaemic control which we observed. Our results are supported by a previous report which found similar heterogeneity in the clinical course of patients with Type I diabetes depending on their ICA titre [13] . All the patients were clinically diagnosed with classical Type I diabetes based on the presenting features, e. g. all patients were lean and prone to ketosis. The Type I diagnosis was then supported by the histological finding of beta-cell depletion, an observation we have reported previously [14] . Notably, the betacells of the patients without in situ immunohistological abnormalities were decreased to the same extent as those of the patients with such abnormalities. In addition, we found no significant differences between the two groups in: age, sex, BMI, HbA 1C , urinary C-peptide secretion, signs of antecedent infection, HLA type or disease duration before insulin therapy. Similarly, in data not shown, we found no difference between the AP and AUP groups either in: peripheral lymphocyte subsets (CD3 + cells, CD4 + cells, CD8 + cells, natural killer cells, interleukin-2 receptor positive cells and HLA-DR + cells) or the titre of viral antibodies to mumps, measles, rubella, cytomegalovirus, Epstein-Barr, and coxackie B4 virus. Despite these similarities, the clinical course after disease onset was different between the two groups.
The presence of at least two clinically distinct groups with recent-onset Type I diabetes suggests the existence of at least two different mechanisms leading to beta-cell death. In AP patients, beta-cells appear to be damaged via a cell-mediated autoimmune pathway before and even after the onset of overt diabetes. Our data suggest that CD8 + -cytotoxic T cells have an important pathogenic role. This is based on two observations. Firstly, the CD8 + cells predominate in the infiltrate and secondly we have consistently observed the hyperexpression of MHC class I in the islet cells [2±3] . Our data does not allow us to comment on the pathogenesis of beta-cell destruction in the AUP patients, but we found no evidence for an autoimmune mechanism. We surmise that a genetic disorder or direct viral attack on the pancreas contributed to the decreased beta-cell mass we observed. Others, for example, have reported patients with a clinical diagnosis of Type I diabetes to have an associated mitochondrial DNA mutation and severe loss of beta-cell volume [15] . Another group reported a Type I diabetic patient who was ICA-negative, this apparently having been caused by a cytomegalovirus infection [16] .
We conclude from this study that the heterogeneous clinical course following the onset of Type I diabetes is associated with islet immunological abnormalities seen at diagnosis. The presence of either insulitis or MHC class I hyperexpression is associated with clear clinical evidence of ongoing beta-cell loss.
